SIS Medical
SIS Medical launches three innovative balloon catheters: EasyT, NIC 1.1 hydro and NIC Nano hydro set new standards
DGAP-News: SIS Medical / Key word(s): Regulatory Approval Frauenfeld, September 05, 2018 – SIS Medical, a Swiss manufacturer of innovative cardiology products, is launching three new models of its balloon catheters. EasyT, NIC 1.1 hydro and NIC Nano hydro have characteristics that define new standards for this type of catheters. They also recently obtained approval for the CE marking. The approval will enable products to be marketed within the European Union while also facilitating registration in Asia, South America and some Middle Eastern countries, so that SIS products can also be sold there in the near future. SIS Medical’s balloon catheters are used in interventional cardiology to dilate narrowed and closed heart vessels. This leads to full restoration of the blood flow in the diseased vessels and is providing the heart muscle with sufficient oxygen. Patients suffering from coronary heart disease can therefore improve their physical performance or return to their job within a few days after intervention. The balloon catheters are usually advanced to the narrowed section of the blood vessels using a guide wire and catheter and then inflated with a pressure of 8 – 35 bar, thus dilating the stenosis. Conventional bypass surgery has been reduced by 80 % over the last 30 years by use of this method. In 2015, the Tübingen-based SHS Gesellschaft für Beteiligungsmanagement acquired a stake in SIS Medical as part of growth financing to further expand its research and development activities and significantly increase its international market presence. An important first milestone consisted of moving to a new production facility in Frauenfeld in the Swiss canton of Thurgau at the beginning of 2016. About SIS Medical AG Group: The company develops and produces its catheters in a state-of-the-art production facility in Frauenfeld, Switzerland. SIS Medical AG is majority owned by the medical technology investor SHS (www.shs-capital.eu), which has been supporting the company in its international expansion since 2015. The company’s Managing Directors are co-founder and shareholder Willi Zwahlen, Patrick Looser as CFO and Dr. Fabian Eckermann as COO.
Dr. Reinhard Saller
05.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |